{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:36:09Z","timestamp":1792874169481,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10792-018-0949-4","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T06:50:13Z","timestamp":1528699813000},"page":"1419-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Catching the therapeutic window of opportunity in early initial-onset Vogt\u2013Koyanagi\u2013Harada uveitis can cure the disease"],"prefix":"10.1007","volume":"39","author":[{"suffix":"Jr.","given":"Carl P.","family":"Herbort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abu El Asrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Pav\u00e9sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Hedayatfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhum","family":"Silpa-archa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanapong","family":"Somkijrungroj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,11]]},"reference":[{"issue":"Suppl 31","key":"949_CR1","first-page":"S191","volume":"21","author":"P Emery","year":"2003","unstructured":"Emery P, Seto Y (2003) Role of biologics in early arthritis. Clin Exp Rheumatol 21(Suppl 31):S191\u2013S194","journal-title":"Clin Exp Rheumatol"},{"key":"949_CR2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","volume":"43","author":"VP Nell","year":"2004","unstructured":"Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43:906\u2013914","journal-title":"Rheumatology"},{"key":"949_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/art.22353","volume":"55","author":"A Finckh","year":"2006","unstructured":"Finckh A, Liang MH, van Herckenrode CM, de Pablo P (2006) Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55:864\u2013872","journal-title":"Arthritis Rheum"},{"key":"949_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","volume":"73","author":"JA Nies van","year":"2014","unstructured":"van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH (2014) What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73:861\u2013870","journal-title":"Ann Rheum Dis"},{"key":"949_CR5","first-page":"2004","volume":"42","author":"K Gocho","year":"2001","unstructured":"Gocho K, Kondo I, Yamaki K (2001) Identification of autoreactive T cells in Vogt\u2013Koyanagi\u2013Harada disease. Invest Ophthalmol 42:2004\u20132009","journal-title":"Invest Ophthalmol"},{"key":"949_CR6","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1167\/iovs.04-1273","volume":"46","author":"FM Damico","year":"2005","unstructured":"Damico FM, Cunha-Neto E, Goldberg AC, Iwai LK, Hammer J, Kalil J, Yamamoto JH (2005) Vogt T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt\u2013Koyanagi\u2013Harada uveitis. Invest Ophthalmol Vis Sci 46:2465\u20132471","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"949_CR7","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1167\/iovs.05-1547","volume":"47","author":"S Sugita","year":"2006","unstructured":"Sugita S, Takase H, Taguchi C, Imai Y, Kamoi K, Kawaguchi T, Sugamoto Y, Futagami Y, Itoh K, Mochizukil M (2006) Ocular infiltrating CD4+ T cells from patients with Vogt\u2013Koyanagi\u2013Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 47:2547\u20132554","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"949_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AM Abu El-Asrar","year":"2011","unstructured":"Abu El-Asrar AM, Struyf S, Kangave D et al (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol 139:177\u2013184","journal-title":"Clin Immunol"},{"key":"949_CR9","first-page":"234","volume-title":"Essentials in ophthalmology: uveitis and immunological disorders","author":"N Bouchenaki","year":"2004","unstructured":"Bouchenaki N, Herbort CP (2004) Stromal choroiditis. In: Pleyer U, Mondino B (eds) Essentials in ophthalmology: uveitis and immunological disorders. Springer, Berlin, pp 234\u2013253"},{"key":"949_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/02713680802233968","volume":"33","author":"W Fang","year":"2008","unstructured":"Fang W, Yang P (2008) Vogt\u2013Koyanagi\u2013Harada syndrome. Curr Eye Res 33:517\u2013523","journal-title":"Curr Eye Res"},{"key":"949_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ophtha.2006.07.040","volume":"114","author":"P Yang","year":"2007","unstructured":"Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A (2007) Clinical characteristics of Vogt\u2013Koyanagi\u2013Harada syndrome in Chinese patients. Ophthalmology 114:606\u2013614","journal-title":"Ophthalmology"},{"key":"949_CR12","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1111\/aos.12127","volume":"91","author":"AM Abu El-Asrar","year":"2013","unstructured":"Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D (2013) Prognostic factors for clinical outcomes in patients with Vogt\u2013Koyanagi\u2013Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 91:e486\u2013e493","journal-title":"Acta Ophthalmol"},{"key":"949_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10792-007-9052-y","volume":"27","author":"A Mantovaqni","year":"2007","unstructured":"Mantovaqni A, Resta A, Herbort CP, Abu El Asrar A, Kawaguchi T, Mochizuki M, Okada AA, Rao N (2007) Work-up, diagnosis and management of acute Vogt\u2013Koyanagi\u2013Harada disease: a case of acute myopization with granulomatous uveitis. Int Ophthalmol 27:105\u2013115","journal-title":"Int Ophthalmol"},{"key":"949_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10384-015-0377-1","volume":"59","author":"C Iwahashi","year":"2015","unstructured":"Iwahashi C, Okuno K, Hashida N, Nakai K, Ohguro N, Nishida K (2015) Incidence and clinical features of recurrent Vogt\u2013Koyanagi\u2013Harada disease in Japanese individuals. Jpn J Ophthalmol 59:157\u2013163","journal-title":"Jpn J Ophthalmol"},{"key":"949_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0039-6257(05)80105-5","volume":"39","author":"RS Moorthy","year":"1995","unstructured":"Moorthy RS, Inomata H, Rao NA (1995) Vogt\u2013Koyanagi\u2013Harada syndrome. Surv Ophthalmol 39:265\u2013292","journal-title":"Surv Ophthalmol"},{"key":"949_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10792-006-9001-1","volume":"27","author":"I Tugal-Tutkun","year":"2007","unstructured":"Tugal-Tutkun I, Ozyazgan Y, Akova Y, Sullu Y, Akyol N, Soylu M, Kazoglu H (2007) The spectrum of Vogt\u2013Koyanagi\u2013Harada disease in Turkey: VKH in Turkey. Int Ophthalmol 27:117\u2013123","journal-title":"Int Ophthalmol"},{"key":"949_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1055\/s-2000-10987","volume":"216","author":"N Bouchenaki","year":"2000","unstructured":"Bouchenaki N, Morisod L, Herbort CP (2000) Vogt\u2013Koyanagi\u2013Harada disease: importance of rapid diagnosis and therapeutic intervention. Klin Monbl Augenheilkd 216:290\u2013294","journal-title":"Klin Monbl Augenheilkd"},{"key":"949_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00417-014-2904-z","volume":"253","author":"VM Sakata","year":"2015","unstructured":"Sakata VM, da Silva FT, Hirata CE, Marin ML, Rodrigues H, Kalil J, Costa RA, Yamamoto JH (2015) High-rate of clinical recurrence in patients with Vogt\u2013Koyanagi\u2013Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol 253:785\u2013790","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"949_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10792-006-9009-6","volume":"27","author":"SP Chee","year":"2007","unstructured":"Chee SP, Jap A, Bascal K (2007) Spectrum of Vogt\u2013Koyanagi\u2013Harada disease in Singapore. Int Ophthalmol 27:137\u2013142","journal-title":"Int Ophthalmol"},{"key":"949_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00417-002-0538-z","volume":"240","author":"H Keino","year":"2002","unstructured":"Keino H, Goto H, Usui M (2002) Sunset glow fundus in Vogt\u2013Koyanagi\u2013Harada disease with or without chronic ocular inflammation. Graefe\u2019s Arch Clin Exp Ophthalmol 240:878\u2013882","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"4","key":"949_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/09273948.2016.1139730","volume":"25","author":"AM Abu El-Asrar","year":"2017","unstructured":"Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, Hemachandran S, Hariz R, Mousa A, Al-Muammar A (2017) Chronic recurrent Vogt\u2013Koyanagi\u2013Harada disease and development of \u201csunset glow fundus\u201d predict a worse retinal sensitivity. Ocul Immunol Inflamm 25(4):475\u2013485. \n                    https:\/\/doi.org\/10.3109\/09273948.2016.1139730","journal-title":"Ocul Immunol Inflamm"},{"key":"949_CR22","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ajo.2006.01.017","volume":"141","author":"H Keino","year":"2006","unstructured":"Keino H, Goto H, Mori H, Iwasaki T, Usui M (2006) Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt\u2013Koyanagi\u2013Harada disease. Am J Ophthalmol 141:1140\u20131142","journal-title":"Am J Ophthalmol"},{"key":"949_CR23","first-page":"542","volume":"23","author":"TY Lai","year":"2009","unstructured":"Lai TY, Chan RP, Chan CK, Lam DS (2009) Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt\u2013Koyanagi\u2013Harada disease. Eye 23:542\u2013548","journal-title":"Eye"},{"key":"949_CR24","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1111\/j.1755-3768.2012.02498.x","volume":"90","author":"AM Abu El-Asrar","year":"2012","unstructured":"Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM (2012) The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt\u2013Koyanagi\u2013Harada disease. Acta Ophthalmol 90:e603\u2013e608","journal-title":"Acta Ophthalmol"},{"key":"949_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09273940500536766","volume":"14","author":"I Paredes","year":"2006","unstructured":"Paredes I, Ahmed M, Foster CS (2006) Immunomodulatory therapy for Vogt\u2013Koyanagi\u2013Harada patients as first-line therapy. Ocul Immunol Inflamm 14:87\u201390","journal-title":"Ocul Immunol Inflamm"},{"key":"949_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/aos.13189","volume":"95","author":"Abu El-Asrar","year":"2017","unstructured":"El-Asrar Abu, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A (2017) Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of \u2018sunset glow fundus\u2019 in initial-onset acute uveitis associated with Vogt\u2013Koyanagi\u2013Harada disease. Acta Ophthalmol 95:85\u201390","journal-title":"Acta Ophthalmol"},{"key":"949_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09273948.2016.1167223","volume":"24","author":"C Couto","year":"2016","unstructured":"Couto C, Schlaen A, Frick M, Khoury M, Lopez M, Hurtado E, Goldstein D (2016) Adalimumab treatment in patients with Vogt\u2013Koyanagi\u2013Harada disease. Ocul Immunol Inflamm 24:1\u20135","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"949_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2415-12-40","volume":"13","author":"FT Silva Da","year":"2012","unstructured":"Da Silva FT, Hirata CE, Sakata VM, Olivalves E, Preti R, Pimentel SL, Gomes A, Takahashi WY, Costa RA, Yamamoto JH (2012) Indocyanine green angiography findings in patients with long-standing Vogt\u2013Koyanagi\u2013Harada disease: a cross-sectional study. BMC Ophthalmol 13(12):40. \n                    https:\/\/doi.org\/10.1186\/1471-2415-12-40","journal-title":"BMC Ophthalmol"},{"key":"949_CR29","first-page":"241","volume":"6","author":"N Bouchenaki","year":"2011","unstructured":"Bouchenaki N, Herbort CP (2011) Indocyanine green angiography guided management of Vogt\u2013Koyanagi\u2013Harada disease. J Ophthalmic Vis Res 6:241\u2013248","journal-title":"J Ophthalmic Vis Res"},{"key":"949_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ajo.2007.10.012","volume":"145","author":"K Bascal","year":"2008","unstructured":"Bascal K, Wen DS, Chee SP (2008) Concomitant choroidal inflammation during anterior segment recurrence in Vogt\u2013Koyanagi\u2013Harada disease. Am J Ophthalmol 145:480\u2013486","journal-title":"Am J Ophthalmol"},{"key":"949_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10792-007-9076-3","volume":"27","author":"M Miyanaga","year":"2007","unstructured":"Miyanaga M, Kawaguchi T, Shimizu K, Miyata Michizuki M (2007) Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt\u2013Koyanagi\u2013Harada disease. Int Ophthalmol 27:183\u2013188","journal-title":"Int Ophthalmol"},{"key":"949_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10792-008-9288-1","volume":"30","author":"T Kawaguchi","year":"2010","unstructured":"Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP (2010) Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt\u2013Koyanagi\u2013Harada disease. Int Ophthalmol 30:41\u201350","journal-title":"Int Ophthalmol"},{"key":"949_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1590\/S0004-27492009000300028","volume":"72","author":"FM Damico","year":"2009","unstructured":"Damico FM, Bezzera FT, Silva GC, Gasparin F, Yamamoto JH (2009) New insights into Vogt\u2013Koyanagi\u2013Harada disease. Arq Bras Oftalmol 72:413\u2013420","journal-title":"Arq Bras Oftalmol"},{"key":"949_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09273940600976938","volume":"14","author":"M Agarwal","year":"2006","unstructured":"Agarwal M, Ganesh SK, Biswas J (2006) Triple agent immunosuppressive therapy in Vogt\u2013Koyanagi\u2013Harada syndrome. Ocul Immunol Inflamm 14:333\u2013339","journal-title":"Ocul Immunol Inflamm"},{"key":"949_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10792-007-9062-9","volume":"27","author":"AS Al-Kharashi","year":"2007","unstructured":"Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D, Abu El-Asrar AM (2007) Prognostic factors in Vogt\u2013Koyanagi\u2013Harada disease. Int Ophthalmol 27:201\u2013210","journal-title":"Int Ophthalmol"},{"issue":"3","key":"949_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10792-013-9861-0","volume":"34","author":"PB Knecht","year":"2014","unstructured":"Knecht PB, Papadia M, Herbort CP (2014) Early and sustained treatment modifies the phenotype of birdshot retinochoroiditis. Int Ophthalmol 34(3):563\u2013574","journal-title":"Int Ophthalmol"},{"key":"949_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1167\/iovs.16-20783","volume":"58","author":"CA Urzua","year":"2017","unstructured":"Urzua CA, Guerrero J, Gatica H, Velasquez V, Goecke A (2017) Evaluation of glucocortcoid receptor as a biomarker of treatment response in Vogt\u2013Koyanagi\u2013Harada disease. Invest Ophthalmol Vis Sci 58:974\u2013980","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"949_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10792-007-9060-y","volume":"27","author":"CP Herbort","year":"2007","unstructured":"Herbort CP, Mantovani A, Bouchenaki N (2007) Indocyanine green angiography in Vogt\u2013Koyanagi\u2013Harada disease: angiographic signs and utility in patient follow-up. Int Ophthalmol 27:173\u2013182","journal-title":"Int Ophthalmol"},{"key":"949_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10384-010-0853-6","volume":"54","author":"M Miyanaga","year":"2010","unstructured":"Miyanaga M, Kawaguchi T, Miyata K, Horie S, Mochizuki M, Herbort CP (2010) Indocyanine green angiography findings in initial acute pre-treatment Vogt\u2013Koyanagi\u2013Harada disease in Japanese patients. Jpn J Ophthalmol 54:377\u2013382","journal-title":"Jpn J Ophthalmol"},{"key":"949_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12974","author":"MA Abouammoh","year":"2016","unstructured":"Abouammoh MA, Gupta V, Hemachandran S, Herbort CP, Abu El-Asrar AM (2016) Indocyanine green angiography in initial-onset acute Vogt\u2013Koyanagi\u2013Harada disease. Acta Ophthalmol. \n                    https:\/\/doi.org\/10.1111\/aos.12974","journal-title":"Acta Ophthalmol"},{"key":"949_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0021-5155(99)00016-7","volume":"43","author":"S Suzuki","year":"1999","unstructured":"Suzuki S (1999) Quantitative evaluation of sunset glow fundus in Vogt\u2013Koyanagi\u2013Harada disease. Jpn J Ophthalmol 43:327\u2013333","journal-title":"Jpn J Ophthalmol"},{"key":"949_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bjophthalmol-2012-302538","volume":"97","author":"SP Chee","year":"2013","unstructured":"Chee SP, Jap A (2013) The outcomes of indocyanine green angiography monitored immunotherapy in Vogt\u2013Koyanagi\u2013Harada disease. Br J Ophthalmol 97:130\u2013133","journal-title":"Br J Ophthalmol"},{"key":"949_CR43","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10792-016-0303-7","volume":"37","author":"O Balci","year":"2017","unstructured":"Balci O, Gasc A, Jeanin B, Herbort CP Jr (2017) Enhanced depth imaging is less suited than indocyanine green angiography for close monitoring of primary choroiditis: a pilot study. Int Ophthalmol 37:737\u2013748","journal-title":"Int Ophthalmol"},{"key":"949_CR44","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/archopht.1991.01080050096037","volume":"109","author":"PE Rubsamen","year":"1991","unstructured":"Rubsamen PE, Gass JDM (1991) Vogt\u2013Koyanagi\u2013Harada syndrome: clinical course, therapy, and complications. Arch Ophthalmol 109:682\u2013687","journal-title":"Arch Ophthalmol"},{"key":"949_CR45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s10792-016-0395-0","volume":"37","author":"CP Herbort Jr","year":"2017","unstructured":"Herbort CP Jr, Abu El Asrar AM, Yamamoto JH, Pav\u00e9sio CE, Gupta V, Khairallah M, Tugal-Tutkun I, Soheilian M, Takeuchi M, Papadia M (2017) Reappraisal of the management of Vogt\u2013Koyanagi\u2013Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol 37:1383\u20131395","journal-title":"Int Ophthalmol"},{"key":"949_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311691","author":"M Nakayama","year":"2018","unstructured":"Nakayama M, Keino H, Watanabe T, Okada AA (2018) Clinical features and visual outcomes of 11 patients with new-onset acute Vogt\u2013Koyanagi\u2013Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311691\n                    \n                  \n                           (Epub ahead of print 18th April 2018)","journal-title":"Br J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-018-0949-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-018-0949-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-018-0949-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:52:34Z","timestamp":1581965554000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-018-0949-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1007\/s10792-018-0949-4","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,11]]},"assertion":[{"value":"22 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}